enGene Q3 2026 cash $266.3M; net loss $32.5M
For the quarter ended July 31, 2026, enGene reported cash, cash equivalents and marketable securities of $266.3 million and a net loss of $32.5 million (about $0.47 per share). Operating expenses were $34.0 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.